Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

Summary

This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.

Timeline

Start

2017-05-15

Primary completion

2017-08-31

Completion

2017-08-31

Drugs

Indications